Human Genome Epidemiology Literature Finder
|
Records 1 - 3 (of 3 Records) |
| Query Trace: Myocardial Infarction and CYP2D6[original query] |
|---|
| Polymorphisms in CYP2D6 may predict methamphetamine related heart failure. Clinical toxicology (Philadelphia, Pa.) 2013 Aug 51 (7): 540-4. Sutter M E, Gaedigk A, Albertson T E, Southard J, Owen K P, Mills L D, Diercks D |
| Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study. European journal of clinical pharmacology 2020 Jan . Anstensrud Anne Kristine, Molden Espen, Haug Hans Jørgen, Qazi Rehman, Muriq Hysen, Fosshaug Linn E, Spigset Olav, Øie Er |
| Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy. Clinical pharmacology and therapeutics 2024 7 . Julio D Duarte, Cameron D Thomas, Craig R Lee, Rachel Huddart, Jose A G Agundez, Jordan F Baye, Andrea Gaedigk, Teri E Klein, David E Lanfear, Andrew A Monte, Mohamed Nagy, Matthias Schwab, C Michael Stein, Chakradhara Rao S Uppugunduri, Ron H N van Schaik, Roseann S Donnelly, Kelly E Caudle, Jasmine A Luz |
- Page last reviewed:Feb 1, 2024
- Content source: